Jade Biosciences
JBIO
78 hedge funds and large institutions have $273M invested in Jade Biosciences in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
4% more funds holding
Funds holding: 75 → 78 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
13% less capital invested
Capital invested by funds: $315M → $273M (-$42.2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $915K
3,705.01% less ownership
Funds ownership: 3,801.92% → 96.91% (-3,705%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.56M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.48M |
| 3 |
Goldman Sachs
New York
|
+$1.33M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$879K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.93M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.87M |
| 3 |
Barclays
London,
United Kingdom
|
-$1.87M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.06M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$661K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
76
TCG Crossover Management
Palo Alto,
California
| – | -$640K | -64,023 | Closed |
|
77
Kovitz Investment Group Partners
Chicago,
Illinois
| – | -$64.9K | -24,210 | Closed |
|
|
AV
78
Alamea Verwaltungs
Edison,
New Jersey
| – | -$512 | -204 | Closed |
|
79
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$515 | -63 | -53% |
|
|
GIM
80
Glenmede Investment Management
Philadelphia,
Pennsylvania
| – | -$529 | -53 | Closed |
|
JBIO Hedge Fund Activity: Q3 2025 in Review
78 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q3 2025, worth a combined $273M — down 13% from $315M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new JBIO positions and 5 closed out — a net gain of 3 holders — while 22 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $3.56M. The largest seller was Frazier Life Sciences Management, cutting an estimated $2.93M.
- 78 institutional investors held Jade Biosciences (JBIO) as of Q3 2025, up from 75 in Q2 2025.
- Funds reported $273M of Jade Biosciences stock for Q3 2025, down 13% quarter-over-quarter.
- 8 funds opened new Jade Biosciences positions in Q3 2025 and 5 closed out, a net change of +3 holders.
- The largest Jade Biosciences buyer in Q3 2025 was BlackRock, an estimated $3.56M added.
- The largest Jade Biosciences seller in Q3 2025 was Frazier Life Sciences Management, an estimated $2.93M sold.
Based on aggregated 13F filings for Q3 2025.